N. Ireland may reinstate drug charges for patients; Orphan-drug spending in Europe sustainable through 2020;

@FiercePharma:  European spending on orphan drugs 'sustainable to 2020.' Growth expected to flatten beginning 2016. Item | Follow @FiercePharma

> Northern Ireland is considering re-introducing charges for prescription drugs after last year's move to abolish them cost the health service more than expected. News

> European spending on orphan drugs, which has been growing fast enough to worry budget-minded policymakers, is expected to be sustainable through 2020, a new analysis finds. Story

> Japan's Miraca Holdings, which makes diagnostic drugs and equipment, agreed to buy a pathology business from Texas-based Caris Life Sciences for $725 million. Item

> A synthetic estrogen known as DES, which many pregnant women took years ago to prevent miscarriage, increased the risk of breast cancer and other health problems in the daughters of those women, a study found. Article

> Uganda's Quality Chemicals is set to begin manufacturing a version of the antiretroviral drug tenofovir, sold by Gilead Sciences under the brand name Viread. News

> AstraZeneca ($AZN) bought back 509,424 of its own shares for 2926 pence per share as part of its ongoing stock repurchasing program. Report

Biotech News

@FierceBiotech:  Report: Prospect Venture dumps latest fund, won't make new biotech bets. Story | Follow @FierceBiotech

@ JohnCFierce: Interesting Q&A from Pharmalot with UC Davis's Rogawski, who wants ALL trial data published, winners and losers. Item | Follow @JohnCFierce

@RyanMFierce: Sounds like a person experimenting with drugs for the right reasons. Nobel winner tried to cure own cancer before death. News | Follow @RyanMFierce

> Nobel winner fought his cancer with own research until death. Item

> Exclusive: Tolerx cuts staff, auctioning assets after PhIII failure. News 

> Report: Prospect Venture dumps latest fund, won't make new biotech bets. Report 

And Finally... Poor controls on antibiotics in China spawns increasing drug resistance. Piece

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…